Adel H Mansur1, Kirsten Kaiser. 1. Chest Research Institute, Birmingham Heartlands Hospital, Birmingham B9 5SS, United Kingdom. Adel.Mansur@heartofengland.nhs.uk
Abstract
BACKGROUND: The long-term safety of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol; flutiform(®)) was assessed. METHOD: In an open-label study, mild to moderate-severe asthmatics (≥12 years; N=472) were treated twice daily with fluticasone/formoterol 100/10 μg (n=224) or 250/10 μg (n=248) for 6 months (n=256) or 12 months (n=216). The primary and secondary objectives were the long-term safety and efficacy of fluticasone/formoterol, respectively. RESULTS: In total, 413 (87.5%) patients completed the study (of which 175 participated for 12 months). Adverse events (AEs) were reported by 174 patients (36.9%): 67 (29.9%) in the 100/10 μg group and 107 (43.1%) in the 250/10 μg group. The most common AEs (>2%) were nasopharyngitis, dyspnea, pharyngitis, and headache; the majority were mild to moderate. Only 18 (3.8%) patients reported AEs considered study drug-related. Five patients per group experienced 12 serious AEs; none was study medication-related. Asthma exacerbations were reported by 53 patients (11.2%): 46 mild to moderate and nine severe. Clinical laboratory tests and vital signs showed no abnormal trends or clinically important or dose-response-related changes. The efficacy analyses showed statistically significant improvements at every time point throughout the study period at both doses. CONCLUSION:Fluticasone/formoterol had a good safety and efficacy profile over the 6- and 12-month study periods.
RCT Entities:
BACKGROUND: The long-term safety of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol; flutiform(®)) was assessed. METHOD: In an open-label study, mild to moderate-severe asthmatics (≥12 years; N=472) were treated twice daily with fluticasone/formoterol 100/10 μg (n=224) or 250/10 μg (n=248) for 6 months (n=256) or 12 months (n=216). The primary and secondary objectives were the long-term safety and efficacy of fluticasone/formoterol, respectively. RESULTS: In total, 413 (87.5%) patients completed the study (of which 175 participated for 12 months). Adverse events (AEs) were reported by 174 patients (36.9%): 67 (29.9%) in the 100/10 μg group and 107 (43.1%) in the 250/10 μg group. The most common AEs (>2%) were nasopharyngitis, dyspnea, pharyngitis, and headache; the majority were mild to moderate. Only 18 (3.8%) patients reported AEs considered study drug-related. Five patients per group experienced 12 serious AEs; none was study medication-related. Asthma exacerbations were reported by 53 patients (11.2%): 46 mild to moderate and nine severe. Clinical laboratory tests and vital signs showed no abnormal trends or clinically important or dose-response-related changes. The efficacy analyses showed statistically significant improvements at every time point throughout the study period at both doses. CONCLUSION:Fluticasone/formoterol had a good safety and efficacy profile over the 6- and 12-month study periods.
Authors: David B Price; Victoria Carter; Jessica Martin; Elizabeth A Gardener; Derek Skinner; Sen Yang; Matthias Hoffman; Jenna C Willis; Andrew J Cooper Journal: Drugs Date: 2020-01 Impact factor: 9.546
Authors: A Papi; D Dokic; W Tzimas; I Mészáros; A Olech-Cudzik; Z Koroknai; K McAulay; S Mersmann; P S Dalvi; T Overend Journal: Int J Chron Obstruct Pulmon Dis Date: 2017-07-05